2020
Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV
Eyawo O, Deng Y, Dziura J, Justice AC, McGinnis K, Tate JP, Rodriguez‐Barradas M, Hansen NB, Maisto SA, Marconi VC, O’Connor P, Bryant K, Fiellin DA, Edelman EJ. Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV. Alcohol Clinical And Experimental Research 2020, 44: 2053-2063. PMID: 33460225, PMCID: PMC8856627, DOI: 10.1111/acer.14435.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useSignificant alcohol useHeavy drinking daysAlcohol use disorderTimeline FollowbackAlcohol useSelf-reported alcohol useNumber of drinksClinical trialsRisk drinkingUse disordersDrinking daysBiomarker-based evidenceSample of PWHDrinks/dayMean numberSelf-reported alcohol consumptionMagnitude of associationBlood spot samplesLiver diseasePEth levelsTLFB interviewAlcohol consumptionLogistic regressionPatients
2019
Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial. Journal Of Substance Use And Addiction Treatment 2019, 106: 97-106. PMID: 31540617, PMCID: PMC7244228, DOI: 10.1016/j.jsat.2019.08.007.Peer-Reviewed Original Research
2016
Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, O'Connor PG, Bedimo R, Gibert C, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Justice AC, Bryant KJ, Fiellin DA. Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients. Contemporary Clinical Trials 2016, 52: 80-90. PMID: 27876616, PMCID: PMC5253227, DOI: 10.1016/j.cct.2016.11.008.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useAlcohol use disorderHIV-positive patientsMotivational enhancement therapyAlcohol useWeek 12Risk drinkingWeek 4Effective evidence-based treatmentsInfectious disease clinicHIV-positive individualsModerate alcohol useEvidence-based treatmentsParticipants meeting criteriaImplementation of interventionsVACS IndexHIV careSecondary outcomesCare trialsDisease clinicHIV morbidityPrimary outcomeAlcohol pharmacotherapyInitial treatmentLiver disease
2013
Nonsteroidal anti‐inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion?
Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti‐inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion? Hepatology 2013, 58: 819-821. PMID: 23703812, DOI: 10.1002/hep.26498.Peer-Reviewed Original Research
2011
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2011, 108: 16381-16385. PMID: 21930939, PMCID: PMC3182681, DOI: 10.1073/pnas.1113359108.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseHepatic DAG contentInsulin resistanceHepatic insulin resistanceLiver diseaseHepatic steatosisCellular mechanismsHomeostatic model assessmentInsulin resistance indexMarkers of inflammationType 2 diabetesER stress markersLipid dropletsHepatic diacylglycerol contentEndoplasmic reticulum stressActivation of PKCεLiver biopsyNondiabetic individualsHepatocellular lipidsInsulin sensitivityCytoplasmic lipid dropletsDAG contentResistance indexAnimal models
2010
Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease
Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease. New England Journal Of Medicine 2010, 362: 1082-1089. PMID: 20335584, PMCID: PMC2976042, DOI: 10.1056/nejmoa0907295.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseasePlasma triglyceride clearanceLiver diseaseFat tolerance testPlasma triglyceride concentrationsInsulin resistanceApolipoprotein C3Wild-type homozygotesIndian menTriglyceride clearanceTriglyceride concentrationsC3 concentrationsTriglyceride contentApolipoprotein C3 gene variantsHealthy Asian Indian menOral fat tolerance testType 2 diabetes mellitusVariant allelesIntravenous fat tolerance testLiver triglyceride contentHepatic triglyceride contentSingle nucleotide polymorphismsVariant allele carriersHepatic insulin resistance
2006
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men
Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Man C, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 18273-18277. PMID: 17114290, PMCID: PMC1693873, DOI: 10.1073/pnas.0608537103.Peer-Reviewed Original ResearchConceptsAsian Indian menInsulin resistanceInsulin sensitivity indexLiver diseaseNonalcoholic fatty liver diseaseOral glucose tolerance testType 2 diabetes mellitusAsian IndiansWhole-body insulin sensitivityFatty liver diseaseIL-6 concentrationsTreatment of T2DMIntramyocellular lipid contentGlucose tolerance testPathogenesis of T2DMProton magnetic resonance spectroscopyImportant therapeutic implicationsEthnic groupsDiabetes mellitusImportant ethnic differencesCaucasian manTolerance testInsulin sensitivityIntramyocellular lipidsLean individuals